These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Fundamental and clinical evaluation of 9,3"-diacetylmidecamycin in pediatric field (author's transl)].
    Author: Iwasaki Y, Iwata S, Kanemitsu T, Jozaki K, Hattori H, Wakabayashi R, Kojima Y, Sunakawa K, Oikawa T, Osano M, Ichihashi Y, Kuratsuji T.
    Journal: Jpn J Antibiot; 1982 Feb; 35(2):429-37. PubMed ID: 6979642.
    Abstract:
    1. The dry syrup of MOM was administered orally to 17 patients mainly with heart diseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases, the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20 mg/kg treatment. The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was 60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3 cases. 7. Any pediatric patient did not refuse taking.
    [Abstract] [Full Text] [Related] [New Search]